loading...| Preferred Name | Canakinumab | |
| Synonyms |
|
|
| Definitions |
A recombinant monoclonal antibody targeting human interleukin-1 beta (IL-1b), with anti-inflammatory and immunomodulating activities. Canakinumab binds IL-1b and prevents the binding of IL-1b to the IL-1 receptor and inhibits IL-1b-mediated signaling. This may suppress inflammatory responses mediated by IL-1b. IL-1b, a proinflammatory cytokine, plays a key role in inflammation. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C80971 |
|
| Accepted_Therapeutic_Use_For |
cryopyrin-associated periodic syndrome, Muckle-Wells syndrome, rheumatoid arthritis Muckle-Wells syndrome, rheumatoid arthritis, other inflammatory conditions |
|
| CAS_Registry |
914613-48-2 |
|
| code |
C80971 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
A recombinant monoclonal antibody targeting human interleukin-1 beta (IL-1b), with anti-inflammatory and immunomodulating activities. Canakinumab binds IL-1b and prevents the binding of IL-1b to the IL-1 receptor and inhibits IL-1b-mediated signaling. This may suppress inflammatory responses mediated by IL-1b. IL-1b, a proinflammatory cytokine, plays a key role in inflammation. |
|
| Display_Name |
Canakinumab |
|
| FDA_UNII_Code |
37CQ2C7X93 |
|
| Has_Target | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C173383 http://purl.obolibrary.org/obo/NCIT_C173381 http://purl.obolibrary.org/obo/NCIT_C176424 |
|
| label |
Canakinumab |
|
| Legacy Concept Name |
Canakinumab |
|
| NCI_Drug_Dictionary_ID |
795723 |
|
| PDQ_Closed_Trial_Search_ID |
795723 |
|
| PDQ_Open_Trial_Search_ID |
795723 |
|
| Preferred_Name |
Canakinumab |
|
| prefixIRI |
NCIT:C80971 |
|
| prefLabel |
Canakinumab |
|
| Semantic_Type |
Pharmacologic Substance Immunologic Factor |
|
| UMLS_CUI |
C2718773 |
|
| subClassOf |